David Engelhardt
David Engelhardt has been employed in equity research at TraderFox GmbH since April 2022. David completed his Bachelor's degree in Economics at Friedrich-Alexander-University in Erlangen-Nuremberg in 2018 and subsequently obtained a Master's degree in Business Administration at the University of Bamberg. Since 2019, he has been independently engaged with the topics of stock markets, equities, and capital markets. For the equity magazine, he is mainly responsible for the Hot News section and regularly publishes his own articles there. Since March 2023, he has been reporting as the editor-in-chief for the Traderfox equity magazine Small Caps Investor about small companies with enormous growth potential.
Latest from David Engelhardt
Iovance Biotherapeutics: The Pioneer of Personalized Cancer Therapy on the Brink of Breakthrough
Iovance Biotherapeutics has a first-mover advantage, as the company has commercialized Amtagvi, the...
Target Hospitality: How the Company is Capitalizing on the Infrastructure Boom
Target Hospitality builds and operates turnkey, modular housing facilities for professionals in remote...
AMD: The Rise into the Trillion-Dollar Club
AMD is fully focused on the design of cutting-edge processors and has them manufactured cost-effectively...
Illumina: The Indestructible Foundation of Gene Code Decoding
Illumina secures highly profitable, recurring revenues through the sale of gene sequencing machines...
Semtech: The Unassuming Winner in the Shadow of AI Giants
Semtech benefits disproportionately from the expansion of modern data centers, as its specialized...
CoreCivic: Here's how the Prison Operator is Cashing in on State Infrastructure Bottlenecks
CoreCivic earns its revenue through long-term contracts with U.S. authorities via per diem rates and...
Dell: From PC Pioneer to Powerhouse of the AI Age
Dell Technologies has transformed from a traditional PC manufacturer to a central and essential infrastructure...
Frequency Electronics: Precision Provider in the Shadow of the Space Explosion
Frequency Electronics is a highly specialized US manufacturer of atomic-accurate time and frequency...
Guardant Health: Cancer Detection via Blood Sample - Here's how the Company is Revolutionizing the Diagnostic Market
Guardant Health is a pioneer in liquid-based cancer testing, detecting genetic tumor traces painlessly...
Pulse Biosciences: Precision Strikes in the Nanosecond Range: how the Company is Revolutionizing Medicine
Pulse Biosciences has developed a highly precise, non-thermal method called Nanosecond Pulsed Field...
PBF Energy: The Crude Oil Refiner - How to Squeeze Clean Returns from Dirty Oil
PBF Energy focuses completely on the refining of crude oil and downstream logistics as an independent...
Delek US Holdings: Between Refining Margins, Midstream Stability, and Strategic Change
Delek US primarily generates its revenue in the refining business through the margin between crude...
Kymera Therapeutics: The Biotech Company Is Taking on Billion-Dollar Markets with Targeted Protein Destruction
Through targeted protein degradation, Kymera utilizes a biological recycling system that completely...
Marathon Petroleum: The Underestimated Cash Flow Machine of the US Stock Market
Marathon Petroleum is the largest independent refinery operator in the USA, primarily earning its...
CG Oncology: The Million-Dollar Bet on the Bladder Cancer Breakthrough
CG Oncology is a late-stage biopharma company focusing on the development of a bladder-preserving...
Eton Pharmaceuticals: Specialty Medications as a Growth Guarantee
Eton Pharmaceuticals bypasses the expensive failures of traditional drug research by optimizing and...
Travere Therapeutics: The Covert Monopoly in the Kidney Market
Travere Therapeutics owns the first and only approved therapy for the rare kidney disease FSGS with...
Virtu Financial: The Invisible High-Performance Engine of the Global Markets
Virtu Financial generates its revenues as a leading electronic market maker primarily through the...
Amylyx Pharmaceuticals: The Stock is Seeing a Significant Increase Due to the GLP-1 Success
After the setback with the former hope Relyvrio, Amylyx Pharmaceuticals has successfully realigned...
Moderna: From Pandemic Beneficiary to Cancer Pioneer
Moderna operates a programmable mRNA platform that enables rapid development of medical blueprints...